Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 25 to 36 of 5708 entries
Sorted by: Best Match Show Resources per page
Injectable therapy for Peyronie's disease.

Translational andrology and urology

Chong W, Tan RB.
PMID: 27298778
Transl Androl Urol. 2016 Jun;5(3):310-7. doi: 10.21037/tau.2016.03.15.

Peyronie's disease is a disfiguring and psychologically devastating disease, which continues to pose a significant clinical conundrum to the attending doctor. Many forms of therapy have been trialled but results have been inconsistent at best. Non-surgical therapy revolves around...

Cite
Chong W, Tan RB. Injectable therapy for Peyronie's disease. Transl Androl Urol. 2016;5(3):310-7doi: 10.21037/tau.2016.03.15.
Chong, W., & Tan, R. B. (2016). Injectable therapy for Peyronie's disease. Translational andrology and urology, 5(3), 310-7. https://doi.org/10.21037/tau.2016.03.15
Chong, Weiliang, and Tan, Ronny Ban Wei. "Injectable therapy for Peyronie's disease." Translational andrology and urology vol. 5,3 (2016): 310-7. doi: https://doi.org/10.21037/tau.2016.03.15
Chong W, Tan RB. Injectable therapy for Peyronie's disease. Transl Androl Urol. 2016 Jun;5(3):310-7. doi: 10.21037/tau.2016.03.15. PMID: 27298778; PMCID: PMC4893510.
Copy Download .nbib Format: NLM
A phase II clinical trial of palonosetron for the management of delayed vomiting in gynecological cancer patients receiving paclitaxel/carboplatin therapy.

Molecular and clinical oncology

Takatori E, Shoji T, Miura Y, Nagao M, Takada A, Nagasawa T, Omi H, Kagabu M, Honda T, Sugiyama T.
PMID: 25798254
Mol Clin Oncol. 2015 Mar;3(2):281-286. doi: 10.3892/mco.2015.484. Epub 2015 Jan 09.

There are currently no studies demonstrating the effects of palonosetron on delayed chemotherapy-induced nausea and vomiting (CINV) in gynecological cancer patients receiving chemotherapy with moderately emetogenic chemotherapeutic agents. We conducted a phase II clinical trial to assess the efficacy...

Cite
Takatori E, Shoji T, Miura Y, et al. A phase II clinical trial of palonosetron for the management of delayed vomiting in gynecological cancer patients receiving paclitaxel/carboplatin therapy. Mol Clin Oncol. 2015;3(2):281-286doi: 10.3892/mco.2015.484.
Takatori, E., Shoji, T., Miura, Y., Nagao, M., Takada, A., Nagasawa, T., Omi, H., Kagabu, M., Honda, T., & Sugiyama, T. (2015). A phase II clinical trial of palonosetron for the management of delayed vomiting in gynecological cancer patients receiving paclitaxel/carboplatin therapy. Molecular and clinical oncology, 3(2), 281-286. https://doi.org/10.3892/mco.2015.484
Takatori, Eriko, et al. "A phase II clinical trial of palonosetron for the management of delayed vomiting in gynecological cancer patients receiving paclitaxel/carboplatin therapy." Molecular and clinical oncology vol. 3,2 (2015): 281-286. doi: https://doi.org/10.3892/mco.2015.484
Takatori E, Shoji T, Miura Y, Nagao M, Takada A, Nagasawa T, Omi H, Kagabu M, Honda T, Sugiyama T. A phase II clinical trial of palonosetron for the management of delayed vomiting in gynecological cancer patients receiving paclitaxel/carboplatin therapy. Mol Clin Oncol. 2015 Mar;3(2):281-286. doi: 10.3892/mco.2015.484. Epub 2015 Jan 09. PMID: 25798254; PMCID: PMC4360756.
Copy Download .nbib Format: NLM
One mechanism of glucocorticoid action in asthma may involve the inhibition of IL-25 expression.

Experimental and therapeutic medicine

Lu W, Lu C, Zhang C, Zhang C.
PMID: 28352347
Exp Ther Med. 2017 Feb;13(2):657-661. doi: 10.3892/etm.2016.4002. Epub 2016 Dec 27.

While the mechanism of action of classic cytokines in asthma has received increased attention from researchers, certain non-classical cytokines, such as IL-25, also participate in this mechanism. The present study was performed to investigate the changes in IL-25 (IL-17E)...

Cite
Lu W, Lu C, Zhang C, et al. One mechanism of glucocorticoid action in asthma may involve the inhibition of IL-25 expression. Exp Ther Med. 2016;13(2):657-661doi: 10.3892/etm.2016.4002.
Lu, W., Lu, C., Zhang, C., & Zhang, C. (2017). One mechanism of glucocorticoid action in asthma may involve the inhibition of IL-25 expression. Experimental and therapeutic medicine, 13(2), 657-661. https://doi.org/10.3892/etm.2016.4002
Lu, Wei, et al. "One mechanism of glucocorticoid action in asthma may involve the inhibition of IL-25 expression." Experimental and therapeutic medicine vol. 13,2 (2017): 657-661. doi: https://doi.org/10.3892/etm.2016.4002
Lu W, Lu C, Zhang C, Zhang C. One mechanism of glucocorticoid action in asthma may involve the inhibition of IL-25 expression. Exp Ther Med. 2017 Feb;13(2):657-661. doi: 10.3892/etm.2016.4002. Epub 2016 Dec 27. PMID: 28352347; PMCID: PMC5348697.
Copy Download .nbib Format: NLM
Maytansinoid immunoconjugate IMGN901 is cytotoxic in a three-dimensional culture model of multiple myeloma.

American journal of blood research

Nierste BA, Gunn EJ, Whiteman KR, Lutz RJ, Kirshner J.
PMID: 27335686
Am J Blood Res. 2016 May 18;6(1):6-18. eCollection 2016.

Environmental-mediated drug-resistance (EM-DR) presents a major challenge for therapeutic development. Tissue microenvironment in the form of extracellular matrix, soluble factors, and stroma contribute to EM-DR. In multiple myeloma (MM), drug-resistance has hindered treatment success with 5-year survival rates remaining

Cite
Nierste BA, Gunn EJ, Whiteman KR, et al. Maytansinoid immunoconjugate IMGN901 is cytotoxic in a three-dimensional culture model of multiple myeloma. Am J Blood Res. 2016;6(1):6-18
Nierste, B. A., Gunn, E. J., Whiteman, K. R., Lutz, R. J., & Kirshner, J. (2016). Maytansinoid immunoconjugate IMGN901 is cytotoxic in a three-dimensional culture model of multiple myeloma. American journal of blood research, 6(1), 6-18.
Nierste, Brittany A, et al. "Maytansinoid immunoconjugate IMGN901 is cytotoxic in a three-dimensional culture model of multiple myeloma." American journal of blood research vol. 6,1 (2016): 6-18.
Nierste BA, Gunn EJ, Whiteman KR, Lutz RJ, Kirshner J. Maytansinoid immunoconjugate IMGN901 is cytotoxic in a three-dimensional culture model of multiple myeloma. Am J Blood Res. 2016 May 18;6(1):6-18. eCollection 2016. PMID: 27335686; PMCID: PMC4913235.
Copy Download .nbib Format: NLM
GDP versus ESHAP Regimen in Relapsed and/or Refractory Hodgkin lymphoma: A Comparison Study.

International journal of hematology-oncology and stem cell research

Ramzi M, Rezvani A, Dehghani M.
PMID: 25802695
Int J Hematol Oncol Stem Cell Res. 2015 Jan 01;9(1):10-4.

BACKGROUND: Despite multiple published studies reporting result of salvage regimens for relapsed and refractory Hodgkin's lymphoma, there are no comparisons of different combinations.PATIENTS AND METHODS: A Total of 44 patients identified with refractory or relapsed Hodgkin's Lymphoma were considered...

Cite
Ramzi M, Rezvani A, Dehghani M. GDP versus ESHAP Regimen in Relapsed and/or Refractory Hodgkin lymphoma: A Comparison Study. Int J Hematol Oncol Stem Cell Res. 2015;9(1):10-4
Ramzi, M., Rezvani, A., & Dehghani, M. (2015). GDP versus ESHAP Regimen in Relapsed and/or Refractory Hodgkin lymphoma: A Comparison Study. International journal of hematology-oncology and stem cell research, 9(1), 10-4.
Ramzi, Mani, et al. "GDP versus ESHAP Regimen in Relapsed and/or Refractory Hodgkin lymphoma: A Comparison Study." International journal of hematology-oncology and stem cell research vol. 9,1 (2015): 10-4.
Ramzi M, Rezvani A, Dehghani M. GDP versus ESHAP Regimen in Relapsed and/or Refractory Hodgkin lymphoma: A Comparison Study. Int J Hematol Oncol Stem Cell Res. 2015 Jan 01;9(1):10-4. PMID: 25802695; PMCID: PMC4369228.
Copy Download .nbib Format: NLM
The Effect of a Combination Treatment Using Palonosetron, Promethazine, and Dexamethasone on the Prophylaxis of Postoperative Nausea and Vomiting and QTc Interval Duration in Patients Undergoing Craniotomy under General Anesthesia: A Pilot Study.

Frontiers in medicine

Bergese SD, Puente EG, Antor MA, Capo G, Yildiz VO, Uribe AA.
PMID: 26870733
Front Med (Lausanne). 2016 Feb 02;3:1. doi: 10.3389/fmed.2016.00001. eCollection 2016.

INTRODUCTION: Postoperative nausea and vomiting (PONV) is a displeasing experience that distresses surgical patients during the first 24 h after a surgical procedure. The incidence of postoperative nausea occurs in about 50%, the incidence of postoperative vomiting is about...

Cite
Bergese SD, Puente EG, Antor MA, et al. The Effect of a Combination Treatment Using Palonosetron, Promethazine, and Dexamethasone on the Prophylaxis of Postoperative Nausea and Vomiting and QTc Interval Duration in Patients Undergoing Craniotomy under General Anesthesia: A Pilot Study. Front Med (Lausanne). 2016;3:1doi: 10.3389/fmed.2016.00001.
Bergese, S. D., Puente, E. G., Antor, M. A., Capo, G., Yildiz, V. O., & Uribe, A. A. (2016). The Effect of a Combination Treatment Using Palonosetron, Promethazine, and Dexamethasone on the Prophylaxis of Postoperative Nausea and Vomiting and QTc Interval Duration in Patients Undergoing Craniotomy under General Anesthesia: A Pilot Study. Frontiers in medicine, 31. https://doi.org/10.3389/fmed.2016.00001
Bergese, Sergio D, et al. "The Effect of a Combination Treatment Using Palonosetron, Promethazine, and Dexamethasone on the Prophylaxis of Postoperative Nausea and Vomiting and QTc Interval Duration in Patients Undergoing Craniotomy under General Anesthesia: A Pilot Study." Frontiers in medicine vol. 3 (2016): 1. doi: https://doi.org/10.3389/fmed.2016.00001
Bergese SD, Puente EG, Antor MA, Capo G, Yildiz VO, Uribe AA. The Effect of a Combination Treatment Using Palonosetron, Promethazine, and Dexamethasone on the Prophylaxis of Postoperative Nausea and Vomiting and QTc Interval Duration in Patients Undergoing Craniotomy under General Anesthesia: A Pilot Study. Front Med (Lausanne). 2016 Feb 02;3:1. doi: 10.3389/fmed.2016.00001. eCollection 2016. PMID: 26870733; PMCID: PMC4735400.
Copy Download .nbib Format: NLM
Impaired Spinal Glucocorticoid Receptor Signaling Contributes to the Attenuating Effect of Depression on Mechanical Allodynia and Thermal Hyperalgesia in Rats with Neuropathic Pain.

Frontiers in cellular neuroscience

Wei X, Sun Y, Luo F.
PMID: 28579944
Front Cell Neurosci. 2017 May 19;11:145. doi: 10.3389/fncel.2017.00145. eCollection 2017.

Although depression-induced altered pain perception has been described in several laboratory and clinical studies, its neurobiological mechanism in the central nervous system (CNS), particularly in the spinal dorsal horn, remains unclear. Therefore, in this study, we aimed to clarify...

Cite
Wei X, Sun Y, Luo F. Impaired Spinal Glucocorticoid Receptor Signaling Contributes to the Attenuating Effect of Depression on Mechanical Allodynia and Thermal Hyperalgesia in Rats with Neuropathic Pain. Front Cell Neurosci. 2017;11:145doi: 10.3389/fncel.2017.00145.
Wei, X., Sun, Y., & Luo, F. (2017). Impaired Spinal Glucocorticoid Receptor Signaling Contributes to the Attenuating Effect of Depression on Mechanical Allodynia and Thermal Hyperalgesia in Rats with Neuropathic Pain. Frontiers in cellular neuroscience, 11145. https://doi.org/10.3389/fncel.2017.00145
Wei, Xiao, et al. "Impaired Spinal Glucocorticoid Receptor Signaling Contributes to the Attenuating Effect of Depression on Mechanical Allodynia and Thermal Hyperalgesia in Rats with Neuropathic Pain." Frontiers in cellular neuroscience vol. 11 (2017): 145. doi: https://doi.org/10.3389/fncel.2017.00145
Wei X, Sun Y, Luo F. Impaired Spinal Glucocorticoid Receptor Signaling Contributes to the Attenuating Effect of Depression on Mechanical Allodynia and Thermal Hyperalgesia in Rats with Neuropathic Pain. Front Cell Neurosci. 2017 May 19;11:145. doi: 10.3389/fncel.2017.00145. eCollection 2017. PMID: 28579944; PMCID: PMC5437111.
Copy Download .nbib Format: NLM
Emphysematous Pyelonephritis and Cystitis: Unusual Adverse Events during Concurrent Chemoradiotherapy for Lung Cancer.

Case reports in oncology

Yokoyama T, Shinozaki S, Arimura H, Nakatomi K, Wataya H.
PMID: 28638336
Case Rep Oncol. 2017 Mar 09;10(1):239-243. doi: 10.1159/000463381. eCollection 2017.

Various adverse events can occur during antineoplastic therapy. A 67-year-old diabetic woman developed an emphysematous urinary tract infection (UTI) associated with chemoradiotherapy for lung cancer. She had received weekly carboplatin plus paclitaxel with thoracic radiotherapy and developed a fever...

Cite
Yokoyama T, Shinozaki S, Arimura H, et al. Emphysematous Pyelonephritis and Cystitis: Unusual Adverse Events during Concurrent Chemoradiotherapy for Lung Cancer. Case Rep Oncol. 2017;10(1):239-243doi: 10.1159/000463381.
Yokoyama, T., Shinozaki, S., Arimura, H., Nakatomi, K., & Wataya, H. (2017). Emphysematous Pyelonephritis and Cystitis: Unusual Adverse Events during Concurrent Chemoradiotherapy for Lung Cancer. Case reports in oncology, 10(1), 239-243. https://doi.org/10.1159/000463381
Yokoyama, Tetsuya, et al. "Emphysematous Pyelonephritis and Cystitis: Unusual Adverse Events during Concurrent Chemoradiotherapy for Lung Cancer." Case reports in oncology vol. 10,1 (2017): 239-243. doi: https://doi.org/10.1159/000463381
Yokoyama T, Shinozaki S, Arimura H, Nakatomi K, Wataya H. Emphysematous Pyelonephritis and Cystitis: Unusual Adverse Events during Concurrent Chemoradiotherapy for Lung Cancer. Case Rep Oncol. 2017 Mar 09;10(1):239-243. doi: 10.1159/000463381. eCollection 2017. PMID: 28638336; PMCID: PMC5478188.
Copy Download .nbib Format: NLM
MicroRNA-130b attenuates dexamethasone-induced increase of lipid accumulation in porcine preadipocytes by suppressing PPAR-γ expression.

Oncotarget

Pan S, Cui Y, Dong X, Zhang T, Xing H.
PMID: 29152131
Oncotarget. 2017 Sep 27;8(50):87928-87943. doi: 10.18632/oncotarget.21318. eCollection 2017 Oct 20.

In this study, two experiments were conducted to determine the role of miR-130b in dexamethasone (DEX)-induced lipid accumulation. Porcine preadipocytes were treated with 10

Cite
Pan S, Cui Y, Dong X, et al. MicroRNA-130b attenuates dexamethasone-induced increase of lipid accumulation in porcine preadipocytes by suppressing PPAR-γ expression. Oncotarget. 2017;8(50):87928-87943doi: 10.18632/oncotarget.21318.
Pan, S., Cui, Y., Dong, X., Zhang, T., & Xing, H. (2017). MicroRNA-130b attenuates dexamethasone-induced increase of lipid accumulation in porcine preadipocytes by suppressing PPAR-γ expression. Oncotarget, 8(50), 87928-87943. https://doi.org/10.18632/oncotarget.21318
Pan, Shifeng, et al. "MicroRNA-130b attenuates dexamethasone-induced increase of lipid accumulation in porcine preadipocytes by suppressing PPAR-γ expression." Oncotarget vol. 8,50 (2017): 87928-87943. doi: https://doi.org/10.18632/oncotarget.21318
Pan S, Cui Y, Dong X, Zhang T, Xing H. MicroRNA-130b attenuates dexamethasone-induced increase of lipid accumulation in porcine preadipocytes by suppressing PPAR-γ expression. Oncotarget. 2017 Sep 27;8(50):87928-87943. doi: 10.18632/oncotarget.21318. eCollection 2017 Oct 20. PMID: 29152131; PMCID: PMC5675683.
Copy Download .nbib Format: NLM
Overactivated autophagy contributes to steroid-induced avascular necrosis of the femoral head.

Experimental and therapeutic medicine

Li X, Li YS, Li LJ, Xie X, Yang Y, Deng ZH, Zeng C, Lei GH.
PMID: 28672940
Exp Ther Med. 2017 Jul;14(1):367-372. doi: 10.3892/etm.2017.4508. Epub 2017 May 23.

Steroid-induced avascular necrosis of the femoral head (SANFH) is a mainly bilateral complication of steroid therapy that involves extensive necrosis, and frequently occurs in young and middle-aged individuals, with a high disability rate. Autophagy is an intracellular lysosomal degradation...

Cite
Li X, Li YS, Li LJ, et al. Overactivated autophagy contributes to steroid-induced avascular necrosis of the femoral head. Exp Ther Med. 2017;14(1):367-372doi: 10.3892/etm.2017.4508.
Li, X., Li, Y. S., Li, L. J., Xie, X., Yang, Y., Deng, Z. H., Zeng, C., & Lei, G. H. (2017). Overactivated autophagy contributes to steroid-induced avascular necrosis of the femoral head. Experimental and therapeutic medicine, 14(1), 367-372. https://doi.org/10.3892/etm.2017.4508
Li, Xuan'An, et al. "Overactivated autophagy contributes to steroid-induced avascular necrosis of the femoral head." Experimental and therapeutic medicine vol. 14,1 (2017): 367-372. doi: https://doi.org/10.3892/etm.2017.4508
Li X, Li YS, Li LJ, Xie X, Yang Y, Deng ZH, Zeng C, Lei GH. Overactivated autophagy contributes to steroid-induced avascular necrosis of the femoral head. Exp Ther Med. 2017 Jul;14(1):367-372. doi: 10.3892/etm.2017.4508. Epub 2017 May 23. PMID: 28672940; PMCID: PMC5488415.
Copy Download .nbib Format: NLM
Bosutinib as a fourth-line therapy for a patient with T315I-positive lymphoid blastic phase chronic myeloid leukemia: A case report.

Oncology letters

Komeno Y, Uchida N, Satoh Y, Uryu H, Iwata Y, Masuda A, Iihara K, Yatomi Y, Taniguchi S, Ryu T.
PMID: 28599428
Oncol Lett. 2017 Jun;13(6):4285-4289. doi: 10.3892/ol.2017.5989. Epub 2017 Apr 05.

A 35-year-old male was diagnosed with chronic myeloid leukemia in the chronic phase and was prescribed 100 mg daily dasatinib. However, dasatinib was discontinued due to thrombocytopenia, and within six months, the disease progressed to the lymphoid blastic phase....

Cite
Komeno Y, Uchida N, Satoh Y, et al. Bosutinib as a fourth-line therapy for a patient with T315I-positive lymphoid blastic phase chronic myeloid leukemia: A case report. Oncol Lett. 2017;13(6):4285-4289doi: 10.3892/ol.2017.5989.
Komeno, Y., Uchida, N., Satoh, Y., Uryu, H., Iwata, Y., Masuda, A., Iihara, K., Yatomi, Y., Taniguchi, S., & Ryu, T. (2017). Bosutinib as a fourth-line therapy for a patient with T315I-positive lymphoid blastic phase chronic myeloid leukemia: A case report. Oncology letters, 13(6), 4285-4289. https://doi.org/10.3892/ol.2017.5989
Komeno, Yukiko, et al. "Bosutinib as a fourth-line therapy for a patient with T315I-positive lymphoid blastic phase chronic myeloid leukemia: A case report." Oncology letters vol. 13,6 (2017): 4285-4289. doi: https://doi.org/10.3892/ol.2017.5989
Komeno Y, Uchida N, Satoh Y, Uryu H, Iwata Y, Masuda A, Iihara K, Yatomi Y, Taniguchi S, Ryu T. Bosutinib as a fourth-line therapy for a patient with T315I-positive lymphoid blastic phase chronic myeloid leukemia: A case report. Oncol Lett. 2017 Jun;13(6):4285-4289. doi: 10.3892/ol.2017.5989. Epub 2017 Apr 05. PMID: 28599428; PMCID: PMC5452986.
Copy Download .nbib Format: NLM
Curculigoside regulates proliferation, differentiation, and pro-inflammatory cytokines levels in dexamethasone-induced rat calvarial osteoblasts.

International journal of clinical and experimental medicine

Zhu FB, Wang JY, Zhang YL, Quan RF, Yue ZS, Zeng LR, Zheng WJ, Hou Q, Yan SG, Hu YG.
PMID: 26550143
Int J Clin Exp Med. 2015 Aug 15;8(8):12337-46. eCollection 2015.

BACKGROUND: Curculigoside (CCG), one of the main bioactive phenolic compounds isolated from the rhizome of Curculigo orchioides Gaertn., is reported to prevent bone loss in ovariectomized rats. However, the underlying molecular mechanisms are largely unknown. Therefore, we investigated the...

Cite
Zhu FB, Wang JY, Zhang YL, et al. Curculigoside regulates proliferation, differentiation, and pro-inflammatory cytokines levels in dexamethasone-induced rat calvarial osteoblasts. Int J Clin Exp Med. 2015;8(8):12337-46
Zhu, F. B., Wang, J. Y., Zhang, Y. L., Quan, R. F., Yue, Z. S., Zeng, L. R., Zheng, W. J., Hou, Q., Yan, S. G., & Hu, Y. G. (2015). Curculigoside regulates proliferation, differentiation, and pro-inflammatory cytokines levels in dexamethasone-induced rat calvarial osteoblasts. International journal of clinical and experimental medicine, 8(8), 12337-46.
Zhu, Fang-Bing, et al. "Curculigoside regulates proliferation, differentiation, and pro-inflammatory cytokines levels in dexamethasone-induced rat calvarial osteoblasts." International journal of clinical and experimental medicine vol. 8,8 (2015): 12337-46.
Zhu FB, Wang JY, Zhang YL, Quan RF, Yue ZS, Zeng LR, Zheng WJ, Hou Q, Yan SG, Hu YG. Curculigoside regulates proliferation, differentiation, and pro-inflammatory cytokines levels in dexamethasone-induced rat calvarial osteoblasts. Int J Clin Exp Med. 2015 Aug 15;8(8):12337-46. eCollection 2015. PMID: 26550143; PMCID: PMC4612828.
Copy Download .nbib Format: NLM
Showing 25 to 36 of 5708 entries